Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
49 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Celltrion, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Celltrion, Inc. - Product Pipeline Review - 2014', provides an overview of the Celltrion, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Celltrion, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Celltrion, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Celltrion, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Celltrion, Inc.'s pipeline products Reasons to buy - Evaluate Celltrion, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Celltrion, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Celltrion, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Celltrion, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Celltrion, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Celltrion, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Celltrion, Inc. Snapshot 5 Celltrion, Inc. Overview 5 Key Information 5 Key Facts 5 Alnylam Pharmaceuticals, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Alnylam Pharmaceuticals, Inc. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Alnylam Pharmaceuticals, Inc. - Pipeline Products Glance 14 Alnylam Pharmaceuticals, Inc. - Late Stage Pipeline Products 14 Pre-Registration Products/Combination Treatment Modalities 14 Phase III Products/Combination Treatment Modalities 15 Alnylam Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 Alnylam Pharmaceuticals, Inc. - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 Discovery Products/Combination Treatment Modalities 19 Alnylam Pharmaceuticals, Inc. - Drug Profiles 20 infliximab biosimilar 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 trastuzumab biosimilar 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 rituximab biosimilar 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 CT-P27 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 adalimumab biosimilar 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 bevacizumab biosimilar 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 cetuximab biosimilar 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 CT-P19 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 CT-P26 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 etanercept biosimilar 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 palivizumab biosimilar 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 CT-P24 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 CT-P25 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Alnylam Pharmaceuticals, Inc. - Pipeline Analysis 35 Alnylam Pharmaceuticals, Inc. - Pipeline Products by Target 35 Alnylam Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 37 Celltrion, Inc. - Pipeline Products by Molecule Type 38 Alnylam Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 39 Alnylam Pharmaceuticals, Inc. - Recent Pipeline Updates 41 Alnylam Pharmaceuticals, Inc. - Dormant Projects 45 Alnylam Pharmaceuticals, Inc. - Company Statement 46 Alnylam Pharmaceuticals, Inc. - Locations And Subsidiaries 47 Head Office 47 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 49 Disclaimer 49
List of Tables Celltrion, Inc., Key Information 5 Celltrion, Inc., Key Facts 5 Alnylam Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8 Celltrion, Inc. - Pipeline by Stage of Development, 2014 10 Celltrion, Inc. - Monotherapy Products in Pipeline, 2014 11 Celltrion, Inc. - Partnered Products in Pipeline, 2014 12 Alnylam Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 13 Alnylam Pharmaceuticals, Inc. - Pre-Registration, 2014 14 Alnylam Pharmaceuticals, Inc. - Phase III, 2014 15 Alnylam Pharmaceuticals, Inc. - Phase II, 2014 16 Alnylam Pharmaceuticals, Inc. - Phase I, 2014 17 Alnylam Pharmaceuticals, Inc. - Preclinical, 2014 18 Alnylam Pharmaceuticals, Inc. - Discovery, 2014 19 Celltrion, Inc. - Pipeline by Target, 2014 36 Celltrion, Inc. - Pipeline by Route of Administration, 2014 37 Celltrion, Inc. - Pipeline by Molecule Type, 2014 38 Celltrion, Inc. - Pipeline Products by Mechanism of Action, 2014 40 Alnylam Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 41 Alnylam Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 45
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
